Find a Clinical Trial

Showing 191 - 200 of 235 Trials

A Phase 1/2, Open-Label, Dose-Escalationand -Expansion Study of the Bruton TyrosineKinase-Targeted Protein-Degrader BGB-16673 inPatients With B-Cell Malignancies

Principal Investigator:

Nicole Lamanna, MD

Contact Number:

212-342-5162

NCT Number:

NCT05006716

Population:

Pediatrics

Phase:

I

The purpose of this study is to look at the safety and tolerability of the study drug, BGB- 16673. Another purpose is to determine the range of BGB-16673 doses that can safely be used. BGB-16673 is an experimental drug. This means that it has not been approved for treatment by the US, the Food and Drug Administration (FDA). This research study is the first time that BGB-16673 will be given to humans and therefore the effects of BGB-16673 on humans are not yet known Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have life expectancy more than 6 months - Must be...
A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT05365581

Population:

Adult

Phase:

I

The goal of this study is to see if a study drug called ASP2138 is safe and effective for people diagnosed with tumors known to have Claudin (CLDN) 18.2 expression. CLDN is a group of proteins seen in gastric-specific, gastroesophageal junction (GEJ) or pancreatic cancer types. The study will also see how ASP2138 is processed in the blood. Each participant will complete a number of procedures and blood collections in order to find the best dose of ASP2138. When this dosage is identified, it will be used to evaluate if ASP2138 causes tumors to shrink. ASP2138 will be assessed continuously...
An open-label, multi-center phase I/Ib dose finding and expansion study of HRO761 as single agent and in combinations in patients with Microsatellite Instability-High or Mismatch Repair Deficient advanced solid tumors

Principal Investigator:

Edmond M. Chan, MD

Contact Number:

212-342-5162

NCT Number:

NCT05838768

Population:

Adult

Phase:

I

The main purpose of the study is to find the optimal dose of HRO761 alone or in combination with tislelizumab or irinotecan that can be given to people with certain cancer types called MSI high or dMMR. The new drug being tested in the study, HRO761, is an oral drug that is called a “targeted medicine”: this means that it targets particular processes which may not be working properly in the cancer cells in a participant's body and causing their disease. This is the first time HRO761 is given to people and the first time HRO761 is used in combination with tislelizumab or irinotecan...
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T Plex, Autologous Customized T Cell Receptor Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Pa rticipants with Antigen positive Locally Advanced (Unresectable) or Metastatic

Principal Investigator:

Brian Henick, MD

Contact Number:

212-342-5162

NCT Number:

NCT05973487

Population:

Adult

Phase:

I

The purpose of the study is to learn if the study treatments TSC-204-A0201, TSC 200- A020, and TSC-204-C0702 alone or in combination, referred to as T-Plex, are safe and effective in treating your type of cancer. T-Plex has not yet been approved by the Food and Drug Administration (FDA). This is a first-in-human study, which means that these products have never been administered to humans before. You are unlikely to benefit from taking part in this study. Are you Eligible? (Inclusion Criteria) Must be 18 years or older - Diagnosed with a locally advanced (unresectable) or metastatic solid...
A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)

Principal Investigator:

Jennifer Effie Amengual, MD

Contact Number:

212-342-5162

NCT Number:

NCT04301076

Population:

Adult

Phase:

I

Are you 18 years of age or older? Have you been diagnosed with human T-cell leukemia virus (HTLV)-associated adult T-cell leukemia-lymphoma (ATLL)? Are you able to make regularly scheduled visits to the clinic for treatment and examinations? Are you Eligible? (Inclusion Criteria) The purpose of this study is to test the safety and tolerability (side effects) of adding a study drug called lenalidomide at different doses in combination with the usual treatment with EPOCH chemotherapy. “Dose” is defined as the amount of drug a patient gets, such as 15 mg. These drugs have already...
A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS ASINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTSIN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Principal Investigator:

Aya Haggiagi, MD

Contact Number:

212-342-5162

NCT Number:

NCT05538130

Population:

Adult

Phase:

I

The purpose of this study is to learn about the safety (the impact of the study drug on your body) and the effects of study drug PF-07799544 for specific types of cancer on the body and to find the best dose for treating certain cancers. For BRAF (B-raf proto-oncogene serine/threonine kinase) mutated solid tumors, PF-07799544 may be combined with encorafenib, also known as BRAFTOVI® (an FDA approved cancer medication). The study drug PF-07799544 is an investigational drug because it is not FDA approved for use in this country. The study drug encorafenib is approved in this country and is...
A Phase 1/2, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Metastatic Uveal Melanoma

Principal Investigator:

Alexander Z. Wei, MD

Contact Number:

212-342-5162

NCT Number:

NCT04935229

Population:

Adult

Phase:

I

The purpose of this study is to determine the best level of dose of SD-101 given by hepatic artery infusion (HAI, a method of putting medication directly into your liver) with using Pressure-Enabled Drug Delivery™ (PEDD™) alone or in combination with nivolumab and/or ipilimumab. Also to find out what effects (both good and bad) SD-101 given by HAI with PEDD has on you and your cancer when given alone or with nivolumab and/or ipilimumab. Are you Eligible? (Inclusion Criteria) Must be 18 years or older at time of consent Confirmed diagnosis of metastatic uveal melanoma with liver...
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas

Principal Investigator:

Hua-Jay J Cherng, MD

Contact Number:

212-342-5162

NCT Number:

NCT05279300

Population:

Adult

Phase:

I

This is a study of the experimental drug CS5001 developed by CStone pharmaceutical, in patients with advanced hematological and solid tumors. CS5001 will target certain receptors that are in high levels on cancer cells. This study will look at the anti-tumor activity of CS5001. CS5001 is not approved by any regulatory agency for the treatment of any condition. It is only available in clinical studies such as this one. To date, it has only been tested in animal studies. This is the first time that the study drug will be given to humans. Are you Eligible? (Inclusion Criteria) Are you at least...
An open-label, Phase 1b study to evaluate the safety andtolerability of eflornithine plus temozolomide in patients with newly diagnosed glioblastoma

Principal Investigator:

Maria Diaz Ordonez, MD

Contact Number:

212-342-5162

NCT Number:

NCT05879367

Population:

Adult

Phase:

I

The purpose of this study is to measure how safe eflornithine is in combination with temozolomide in patients with newly diagnosed glioblastoma multiforme (GBM) following radiation therapy. Safety and tolerability will be determined on the basis of physical exams, laboratory tests, and questions about any problems you might experience during the study.This study will also measure levels of eflornithine in patients following dosing, and it will evaluate how effective eflornithine is as a treatment of GBM when combined with temozolomide. Eflornithine is an experimental drug, which means that it...
A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in KRAS

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT05379985

Population:

Pediatrics/Adult

Phase:

I

The purpose of this study is to test an experimental drug called RMC-6236 (the study drug) for solid tumor cancer with a KRAS mutation. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of your cancer cells. RMC-6236 is an experimental drug, which means that it is not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC-6236 will be tested in humans. The safety of...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages